JP2015010091A5 - - Google Patents

Download PDF

Info

Publication number
JP2015010091A5
JP2015010091A5 JP2014124999A JP2014124999A JP2015010091A5 JP 2015010091 A5 JP2015010091 A5 JP 2015010091A5 JP 2014124999 A JP2014124999 A JP 2014124999A JP 2014124999 A JP2014124999 A JP 2014124999A JP 2015010091 A5 JP2015010091 A5 JP 2015010091A5
Authority
JP
Japan
Prior art keywords
ppm
crystalline
value
powder
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014124999A
Other languages
English (en)
Japanese (ja)
Other versions
JP6110817B2 (ja
JP2015010091A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015010091A publication Critical patent/JP2015010091A/ja
Publication of JP2015010091A5 publication Critical patent/JP2015010091A5/ja
Application granted granted Critical
Publication of JP6110817B2 publication Critical patent/JP6110817B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014124999A 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態 Expired - Fee Related JP6110817B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840703P 2013-06-28 2013-06-28
US61/840,703 2013-06-28

Publications (3)

Publication Number Publication Date
JP2015010091A JP2015010091A (ja) 2015-01-19
JP2015010091A5 true JP2015010091A5 (https=) 2016-08-04
JP6110817B2 JP6110817B2 (ja) 2017-04-05

Family

ID=51136530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014124999A Expired - Fee Related JP6110817B2 (ja) 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態

Country Status (8)

Country Link
US (1) US9637500B2 (https=)
EP (1) EP3013835B1 (https=)
JP (1) JP6110817B2 (https=)
AR (1) AR096759A1 (https=)
CA (1) CA2916605C (https=)
ES (1) ES2656189T3 (https=)
TW (1) TW201504246A (https=)
WO (1) WO2014207606A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10159663B2 (en) * 2014-08-20 2018-12-25 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
EP3798222B1 (en) 2015-07-31 2023-11-22 Pfizer Inc. Crystalline form of lorlatinib free base
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
EP3415518B1 (en) 2016-03-03 2020-07-08 Shenzhen TargetRx, Inc. Macrocycle and composition comprising thereof
EP3440086B1 (en) * 2016-04-08 2020-08-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
JP7153069B2 (ja) 2017-10-10 2022-10-13 ファイザー・インク ロルラチニブ遊離塩基水和物の結晶形態
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US20210163498A1 (en) 2018-04-23 2021-06-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
US12077528B2 (en) 2018-11-28 2024-09-03 Shenzhen Targetrx, Inc. Preparation method for deuterated macrocyclic compound
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
EP3999514A1 (en) 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
CN112724077B (zh) * 2020-12-29 2023-07-11 武汉利昌医药科技有限公司 一种劳拉替尼中间体的合成方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases

Similar Documents

Publication Publication Date Title
JP2015010091A5 (https=)
JP2016065042A5 (https=)
JP2014526498A5 (https=)
JP2017039702A5 (https=)
JP2018024682A5 (https=)
WO2016087665A3 (en) Compounds for treating cystic fibrosis
JP2015044837A5 (https=)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
JP2014162794A5 (https=)
JP2011168587A5 (https=)
MX381000B (es) Cristales de compuesto azabicíclico.
EP4643945A8 (en) Neuroactive steroids and methods of use thereof
NZ757221A (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
FI4349406T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
EP2665694A1 (en) Process for the manufacture of 2,3,3,3- tetrafluoropropene by gas phase fluorination of pentachloropropane
JP2013521273A5 (https=)
JP2019510768A5 (https=)
RU2016146119A (ru) Новый кристалл тетрациклического соединения
JP2013503134A5 (https=)
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
IN2014DN09347A (https=)
JP2020536893A5 (https=)
JP2016204373A5 (https=)
JP2015516425A5 (https=)